

- 2C19 loss of function polymorphism and stent thrombosis following percutaneous coronary intervention. *Eur Heart J* 30 (2009): 916-922.
8. Guha S, Sardar P, Guha P, et al. Dual antiplatelet drug resistance in patients with acute coronary syndrome. *Indian Heart J* 61 (2009): 68-73.
 9. Haq MM, Ahsan CH, Amin MN, et al. Comparison of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients undergoing percutaneous coronary intervention. *Bangladesh Med Res Counc Bull.* 39 (2013): 139-145.
 10. Munwar S, Islam AW, Bhuiyan AH, et al. Clopidogrel Resistance in Patient Undergoing Percutaneous Coronary Intervention (PCI): A Single Center Experience in Apollo Hospitals Dhaka. *J Am Coll Cardiol* 73 (2019): S52-S53.
 11. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the anti-platelet effect and clinical efficacy of Clopidogrel therapy. *JAMA* 302 (2009): 849-857.
 12. Price MJ, Tantry US, Gurbel PA. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y12 inhibitors. *Rev Cardiovasc Med* 12 (2011): 1-12.
 13. Sadath AP, Vijayaraghavan G, Kartha CC, et al. Antiplatelet drug resistance in Indians. *Ann Clin Cardiol* 2 (2020): 36-41.
 14. Raju S. Genetic Aspect of Clopidogrel Resistance: An Indian Scenario. *Indian J Cardio Biol Clin Sci* 3 (2016): 107.
 15. KhalafH, AlMeman AA, Rasool S. Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome. *Drug Metab Lett* 10 (2016): 65-70.
 16. Bin Sayeed MS, Hasan Apu MN, Munir MT, et al. Prevalence of CYP2C19 alleles, pharmacokinetic and pharmacodynamic variation of clopidogrel and prasugrel in Bangladeshi population. *Clin Exp Pharmacol Physiol* 42 (2015): 451-457.
 17. Louca JI, Bassem GS, Habib W, et al. The effect of doubling the dose of clopidogrel on platelet aggregation in patients with clopidogrel resistance, *The Egyptian Heart Journal* 66 (2014): 259-262.